SEC Form 4 · accession 0001209191-15-055330

Invuity, Inc. · IVTY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Eric W Roberts

Director

Period of report

Jun 18, 2015

Accepted (ET)

Jun 22, 2015 · 3:35 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001393020

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Jun 18, 2015	C	43,312	—	A	43,312	D
Common Stock^F3,F4,F5	Jun 18, 2015	C	326,086	—	A	326,086	I	See footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series D Preferred Stock^F1	—	Jun 18, 2015	C	31,452	D	—	—	Common Stock	31,728	D
Series E Preferred Stock^F2	—	Jun 18, 2015	C	11,273	D	—	—	Common Stock	11,584	D
Series D Preferred Stock^F5,F3	—	Jun 18, 2015	C	284,460	D	—	—	Common Stock	286,969	I
Series E Preferred Stock^F5,F4	—	Jun 18, 2015	C	38,065	D	—	—	Common Stock	39,117	I

Explanation of responses

F131,452 outstanding shares of Series D Preferred Stock automatically converted into 31,728 shares of Common Stock, on a 1.008821799-for-one basis, immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.
F211,273 outstanding shares of Series E Preferred Stock automatically converted into 11,584 shares of Common Stock, on a 1.027662672-for-one basis, immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.
F3284,460 outstanding shares of Series D Preferred Stock automatically converted into 286,969 shares of Common Stock, on a 1.008821799-for-one basis, immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.
F438,065 outstanding shares of Series E Preferred Stock automatically converted into 39,117 shares of Common Stock, on a 1.027662672-for-one basis, immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. Table II of the Form 3 filed by the reporting person on June 11, 2015 erroneously set forth 38,065 as the number of shares of Common Stock underlying the Series E Preferred Stock; such number should have been set forth as 39,117.
F5The shares are held by Valence CDK SPV, L.P. ("Valence CDK"). Valence Life Sciences GP II, LLC ("Valence") is the General Partner of Valence CDK. The Reporting Person is a Managing Member of Valence and disclaims beneficial ownership of the shares held by Valence CDK, except to the extent of his pecuniary interest therein.